Allogene Therapeutics (ALLO) Share-based Compensation (2018 - 2026)

Allogene Therapeutics has disclosed Share-based Compensation across 9 years of filings, most recently posting $8.3 million for Q1 2026.

• Share-based Compensation for Q1 2026 came in at $8.3 million, down 32.07% year-over-year; the trailing twelve-month figure through Mar 2026 was $33.7 million (down 35.11% YoY), and the FY2025 annual result was $37.6 million, down 27.25% from the prior year.
• Share-based Compensation came in at $8.3 million for Q1 2026 at Allogene Therapeutics, up from $8.1 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $22.9 million in Q2 2022 to a low of $8.1 million in Q4 2025.
• The 5-year median for Share-based Compensation is $13.6 million (2024), against an average of $14.5 million.
• Across the five-year window, Share-based Compensation surged 32.89% in 2022 and sank 36.84% in 2025, its largest moves.
• Allogene Therapeutics' Share-based Compensation stood at $17.2 million in 2022, then retreated by 11.67% to $15.2 million in 2023, then declined by 15.49% to $12.9 million in 2024, then slumped by 36.84% to $8.1 million in 2025, then rose by 1.72% to $8.3 million in 2026.
• The last three Share-based Compensation figures came in at $8.3 million (Q1 2026), $8.1 million (Q4 2025), and $8.7 million (Q3 2025), per Business Quant data.